文献速递临床试验与 GCP

气管内布地奈德混合表面活性剂提高极早产儿无支气管肺发育不良生存率:国际多中心随机PLUSS试验统计分析计划

Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: statistical analysis plan for the international, multicenter, randomized PLUSS trial.
PubMed 文献 · Trials · 2023-11-06

PLUSS试验为国际多中心双盲随机试验,纳入出生<48小时、胎龄<28周的极早产儿,比较气管内布地奈德(0.25 mg/kg)混合猪肺磷脂α(首剂200 mg/kg,二次100 mg/kg)与单用猪肺磷脂α对36周矫正胎龄时无BPD生存的影响。计划样本量1038例(每组519例),目标入组1060例,主要分析采用二元回归估计风险差及95%CI。

要点

  • 极早产儿出生<48小时内接受机械通气或非侵入呼吸支持且临床决定用表面活性剂者符合纳入标准
  • 干预组气管内给予布地奈德0.25 mg/kg混合猪肺磷脂α,对照组单用猪肺磷脂α
  • 主要结局为36周矫正胎龄时无BPD生存,采用二元回归估计两组风险差及95%CI

核心结论

  • PLUSS试验旨在确定气管内布地奈德混合表面活性剂能否提高出生前28周极早产儿36周矫正胎龄时无BPD生存率。

研究设计与样本

  • 国际多中心双盲随机试验,纳入出生<48小时、胎龄<28周的极早产儿,需机械通气或接受非侵入呼吸支持且临床决定使用表面活性剂。
  • 干预为气管内布地奈德0.25 mg/kg混合猪肺磷脂α(首剂200 mg/kg,二次100 mg/kg),对照为单用猪肺磷脂α相同剂量。
  • 计划样本量1038例(每组519例),考虑最多2%退出或失访,目标入组1060例(每组530例)。

主要发现

  • 样本量基于对照组预期无BPD生存率50%、干预组60%(绝对增加10%,相对增加20%),α误差0.05,把握度90%。
  • 主要结局以每组36周矫正胎龄时无BPD存活婴儿的数量和百分比报告。
  • 采用二元回归(恒等链接函数和二项分布的广义线性多变量模型)估计治疗组与对照组间风险差及95%CI。
  • 次要结局包括主要结局组分(死亡、36周矫正胎龄前或时BPD)及皮质类固醇潜在全身副作用。
  • 长期结局将另行发表,包括成本效果、至2岁早期儿童健康及2岁矫正年龄神经发育结局。

关键数值与推荐

  • 主要结局为36周矫正胎龄时无BPD生存。
  • 布地奈德剂量0.25 mg/kg,猪肺磷脂α首剂200 mg/kg、二次100 mg/kg,气管内给药。
  • 样本量1038例提供90%把握度检测无BPD生存相对增加20%(绝对增加10%),α误差0.05。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bronchopulmonary dysplasia (BPD), an inflammatory-mediated chronic lung disease, is common in extremely preterm infants born before 28 weeks' gestation and is associated with an increased risk of adverse neurodevelopmental and respiratory outcomes in childhood. Effective and safe prophylactic therapies for BPD are urgently required. Systemic corticosteroids reduce rates of BPD in the short term but are associated with poorer neurodevelopmental outcomes if given to ventilated infants in the first week after birth. Intratracheal administration of corticosteroid admixed with exogenous surfactant could overcome these concerns by minimizing systemic sequelae. Several small, randomized trials have found intratracheal budesonide in a surfactant vehicle to be a promising therapy to increase survival free of BPD. The primary objective of the PLUSS trial is to determine whether intratracheal budesonide mixed with surfactant increases survival free of bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age (PMA) in extremely preterm infants born before 28 weeks' gestation. METHODS: An international, multicenter, double-blinded, randomized trial of intratracheal budesonide (a corticosteroid) mixed with surfactant for extremely preterm infants to increase survival free of BPD at 36 weeks' postmenstrual age (PMA; primary outcome). Extremely preterm infants aged < 48 h after birth are eligible if (1) they are mechanically ventilated, or (2) they are receiving non-invasive respiratory support and there is a clinical decision to treat with surfactant. The intervention is budesonide (0.25 mg/kg) mixed with poractant alfa (200 mg/kg first intervention, 100 mg/kg if second intervention), administered intratracheally via an endotracheal tube or thin catheter. The comparator is poractant alfa alone (at the same doses). Secondary outcomes include the components of the primary outcome (death, BPD prior to or at 36 weeks' PMA), and potential systemic side effects of corticosteroids. Longer-term outcomes will be published separately, and include cost-effectiveness, early childhood health until 2 years of age, and neurodevelopmental outcomes at 2 years of age (corrected for prematurity). STATISTICAL ANALYSIS PLAN: A sample size of 1038 infants (519 in each group) is required to provide 90% power to detect a relative increase in survival free of BPD of 20% (an absolute increase of 10%), from the anticipated event rate of 50% in the control arm to 60% in the intervention (budesonide) arm, alpha error 0.05. To allow for up to 2% of study withdrawals or losses to follow-up, PLUSS aimed to enroll a total of 1060 infants (530 in each arm). The binary primary outcome will be reported as the number and percentage of infants who were alive without BPD at 36 weeks' PMA for each randomization group. To estimate the difference in risk (with 95% CI), between the treatment and control arms, binary regression (a generalized linear multivariable model with an identity link function and binomial distribution) will be used. Along with the primary outcome, the individual components of the primary outcome (death, and physiological BPD at 36 weeks' PMA), will be reported by randomization group and, again, binary regression will be used to estimate the risk difference between the two treatment groups for survival and physiological BPD at 36 weeks' PMA.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Francis KL, McKinlay CJD, Kamlin COF, et al. Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: statistical analysis plan for the international, multicenter, randomized PLUSS trial. Trials. 2023. PMID: 37932774. doi:10.1186/s13063-023-07650-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。